Documentos relacionados

1. Using (1,3)-ß-D-glucan concentrations in serum to monitor the response of azole therapy in patients with eumycetoma caused by Madurella mycetomatis.
2. Diagnostic implications of mycetoma derived from Madurella pseudomycetomatis isolates from Mexico.
3. Inhibiting DHN- and DOPA-melanin biosynthesis pathway increased the therapeutic value of itraconazole in Madurella mycetomatis infected Galleria mellonella.
4. Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim.
5. The combination of manogepix and itraconazole is synergistic and inhibits the growth of Madurella mycetomatis in vitro but not in vivo.
6. An updated list of eumycetoma causative agents and their differences in grain formation and treatment response.
7. Head and neck mycetoma: Clinical findings, investigations, and predictors for recurrence of the disease in Sudan: A retrospective study.
8. Antifungal Activity of Natural Naphthoquinones and Anthraquinones against Madurella mycetomatis.
9. Eumycetoma causative agents are inhibited in vitro by luliconazole, lanoconazole and ravuconazole.
10. Epidemiological cut-off values for itraconazole and ravuconazole for Madurella mycetomatis, the most common causative agent of mycetoma.